Zobrazeno 1 - 10
of 761
pro vyhledávání: '"Nathan, PD"'
Autor:
Larkin J; The Royal Marsden NHS Foundation Trust, London, United Kingdom., Del Vecchio M; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Mandalá M; Papa Giovanni XIII Hospital, Bergamo, Italy., Gogas H; National and Kapodistrian University of Athens, Athens, Greece., Arance Fernandez AM; Hospital Clínic de Barcelona, Barcelona, Spain., Dalle S; Hospices Civils de Lyon, Pierre Bénite, France., Cowey CL; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas., Schenker M; Oncology Center Sf Nectarie Ltd., Craiova, Romania., Grob JJ; Aix Marseille University, Hôpital de la Timone, Marseille, France., Chiarion-Sileni V; Veneto Institute of Oncology IOV - IRCCS, Padua, Italy., Marquez-Rodas I; General University Hospital Gregorio Marañón and CIBERONC, Madrid, Spain., Butler MO; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Di Giacomo AM; Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy., Middleton MR; Churchill Hospital, Oxford, United Kingdom., Lutzky J; Sylvester Comprehensive Cancer Center, Miami, Florida., de la Cruz-Merino L; Hospital Universitario Virgen Macarena, Clinical Oncology Department, University of Seville, Seville, Spain., Arenberger P; Charles University Third Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic., Atkinson V; Gallipoli Medical Research Foundation, Greenslopes Private Hospital, Greenslopes, Queensland, Australia., Hill AG; Tasman Health Care, Southport, QLD, Australia., Fecher LA; University of Michigan Rogel Cancer Center, Ann Arbor, Michigan., Millward M; University of Western Australia and Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia., Nathan PD; Mount Vernon Hospital, Middlesex, United Kingdom., Khushalani NI; H. Lee Moffitt Cancer Center, Tampa, Florida., Queirolo P; IEO, European Institute of Oncology IRCCS, Milan, Italy., Ritchings C; Bristol Myers Squibb, Princeton, New Jersey., Lobo M; Bristol Myers Squibb, Princeton, New Jersey., Askelson M; Bristol Myers Squibb, Princeton, New Jersey., Tang H; Bristol Myers Squibb, Princeton, New Jersey., Dolfi S; Bristol Myers Squibb, Princeton, New Jersey., Ascierto PA; Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy., Weber J; Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Sep 01; Vol. 29 (17), pp. 3352-3361.
Autor:
Howlett S; Mount Vernon Cancer Centre, Northwood, Middlesex, UK., Carter TJ; Mount Vernon Cancer Centre, Northwood, Middlesex, UK., Shaw HM; Mount Vernon Cancer Centre, Northwood, Middlesex, UK.; University College London Hospital, London, UK., Nathan PD; Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK.
Publikováno v:
Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2023 Mar 21; Vol. 15, pp. 17588359231160140. Date of Electronic Publication: 2023 Mar 21 (Print Publication: 2023).
Autor:
Corrie, PG, Marshall, A, Nathan, PD, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, CG, Marples, M, Danson, SJ, Marshall, E, Houston, SJ, Board, RE, Waterston, AM, Nobes, JP, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, PM, Ottensmeier, CH, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, EO, Harman, C, Weiss, M, Myers, KA, Chhabra, A, Rodwell, SH, Dunn, JA, Middleton, MR, Investigators, AVAST-M
Publikováno v:
ANNALS OF ONCOLOGY
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::8b659aae2c5afd3627b833b57ae597d8
Autor:
Corrie, PG, Marshall, A, Nathan, PD, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, CG, Marples, M, Danson, SJ, Marshall, E, Houston, SJ, Board, RE, Waterston, AM, Nobes, JP, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, PM, Ottensmeier, CH, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, EO, Harman, C, Weiss, M, Myers, KA, Chhabra, A, Rodwell, SH, Dunn, JA, Middleton, MR, AVAST-M Investigators, Nathan, P, Dziewulski, P, Holikova, S, Panwar, U, Thomas, A, Corrie, P, Sirohi, B, Kelly, C, Middleton, M, Danson, S, Lester, J, Ajaz, M, Houston, S, Board, R, Eaton, D, Waterston, A, Nobes, J, Loo, S, Gray, G, Stubbings, H, Marsden, J, Patel, P, Ottensmeier, C, Dega, R, Herbert, C, Price, C, Brunt, M, Scott-Brown, M, Hamilton, J, Hayward, RL, Smyth, J, Woodings, P, Nayak, N, Burrows, L, Wolstenholme, V, Wagstaff, J, Nicolson, M, Wilson, A, Barlow, C, Scrase, C, Podd, T, Gonzalez, M, Stewart, J, Highley, M, Grumett, S, Talbot, T, Nathan, K, Coltart, R, Gee, B
Publikováno v:
Annals of Oncology
Corrie, P G, Marshall, A, Nathan, P D, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, C G, Marples, M, Danson, S J, Marshall, E, Houston, S J, Board, R E, Waterston, A M, Nobes, J P, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, P M, Ottensmeier, C H, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, E O, Harman, C, Weiss, M, Myers, K A, Chhabra, A, Rodwell, S H, Dunn, J A & Middleton, M R 2019, ' Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial ', Annals of Oncology, vol. 30, no. 12, pp. 2013-2014 . https://doi.org/10.1093/annonc/mdz237
Corrie, P G, Marshall, A, Nathan, P D, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, C G, Marples, M, Danson, S J, Marshall, E, Houston, S J, Board, R E, Waterston, A M, Nobes, J P, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, P M, Ottensmeier, C H, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, E O, Harman, C, Weiss, M, Myers, K A, Chhabra, A, Rodwell, S H, Dunn, J A & Middleton, M R 2018, ' Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial ', Ann Oncol., vol. 29, no. 8, pp. 1843-1852 . https://doi.org/10.1093/annonc/mdy229
Corrie, P G, Marshall, A, Nathan, P D, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, C G, Marples, M, Danson, S J, Marshall, E, Houston, S J, Board, R E, Waterston, A M, Nobes, J P, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, P M, Ottensmeier, C H, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, E O, Harman, C, Weiss, M, Myers, K A, Chhabra, A, Rodwell, S H, Dunn, J A & Middleton, M R 2019, ' Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial ', Annals of Oncology, vol. 30, no. 12, pp. 2013-2014 . https://doi.org/10.1093/annonc/mdz237
Corrie, P G, Marshall, A, Nathan, P D, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, C G, Marples, M, Danson, S J, Marshall, E, Houston, S J, Board, R E, Waterston, A M, Nobes, J P, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, P M, Ottensmeier, C H, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, E O, Harman, C, Weiss, M, Myers, K A, Chhabra, A, Rodwell, S H, Dunn, J A & Middleton, M R 2018, ' Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial ', Ann Oncol., vol. 29, no. 8, pp. 1843-1852 . https://doi.org/10.1093/annonc/mdy229
Background Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::106bd17e6b41935f029db129ae87e05b
http://europepmc.org/articles/PMC6096737
http://europepmc.org/articles/PMC6096737
Autor:
Tawbi HA; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA htawbi@mdanderson.org., Robert C; Gustave Roussy, Villejuif, and Paris-Saclay University, Orsay, France., Brase JC; Novartis Pharma AG, Basel, Switzerland., Gusenleitner D; Novartis Institutes for BioMedical Research, Inc, Cambridge, Massachusetts, USA., Gasal E; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA., Garrett J; Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts, USA., Savchenko A; Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts, USA., Görgün G; Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts, USA., Flaherty KT; Dana-Farber Cancer Institute/Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts, USA., Ribas A; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California, USA., Dummer R; University Hospital Zürich Skin Cancer Center, Zürich, Switzerland., Schadendorf D; University Hospital Essen, Essen, and German Cancer Consortium, Heidelberg, Germany., Long GV; Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia., Nathan PD; Mount Vernon Cancer Centre, Northwood, UK., Ascierto PA; Istituto Nazionale Tumori, IRCCS, Fondazione 'G. Pascale', Naples, Italy.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Jun; Vol. 10 (6).
Autor:
Dummer R; University Hospital Zürich Skin Cancer Center, Zürich, Switzerland., Long GV; Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia., Robert C; Gustave Roussy, Villejuif, and Paris-Saclay University, Orsay, France., Tawbi HA; The University of Texas MD Anderson Cancer Center, Houston, TX., Flaherty KT; Dana-Farber Cancer Institute/Harvard Medical School and Massachusetts General Hospital, Boston, MA., Ascierto PA; Istituto Nazionale Tumori, IRCCS, Fondazione 'G. Pascale,' Naples, Italy., Nathan PD; Mount Vernon Cancer Centre, Northwood, United Kingdom., Rutkowski P; Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Leonov O; Clinical Oncological Dispensary, Omsk, Russia., Dutriaux C; Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux, France., Mandalà M; Unit of Medical Oncology, University of Perugia, Perugia, Italy.; Unit of Medical Oncology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy., Lorigan P; University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom., Ferrucci PF; Department of Experimental Oncology, European Institute of Oncology, IRCCS, Milan, Italy., Grob JJ; Timone Hospital AP-HM and Aix-Marseille University, Marseille, France., Meyer N; Université Toulouse III-Paul Sabatier, Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1037-CRCT, Toulouse, France., Gogas H; Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece., Stroyakovskiy D; Moscow City Oncology Hospital, Moscow, Russia., Arance A; Hospital Clinic of Barcelona, Barcelona, Spain., Brase JC; Novartis Pharma AG, Basel, Switzerland., Green S; Novartis Pharma AG, Basel, Switzerland., Haas T; Novartis Pharma AG, Basel, Switzerland., Masood A; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Gasal E; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Ribas A; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA., Schadendorf D; University Hospital Essen, Essen, and German Cancer Consortium, Heidelberg, Germany.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 May 01; Vol. 40 (13), pp. 1428-1438. Date of Electronic Publication: 2022 Jan 14.
Autor:
Brase JC; Novartis Pharma AG, Basel, Switzerland., Walter RFH; Department of Pathology, University Hospital Essen, Essen, Germany.; Ruhrlandklinik, West German Lung Center, University Hospital Essen, University of Duisburg-Essen, Germany., Savchenko A; Oncology Precision Medicine, Novartis, Cambridge, Massachusetts., Gusenleitner D; Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts., Garrett J; Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts., Schimming T; Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.; Department of Dermatology, Fachklinik Hornheide, Münster, Germany., Varaljai R; Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Castelletti D; Novartis Pharma AG, Basel, Switzerland., Kim J; Navigate BioPharma Services, Inc. (a Novartis subsidiary), Carlsbad, California., Dakappagari N; Navigate BioPharma Services, Inc. (a Novartis subsidiary), Carlsbad, California., Schultz K; Oncology Precision Medicine, Novartis, Cambridge, Massachusetts., Robert C; Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif, France., Long GV; Melanoma Institute Australia and Sydney Medical School, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia., Nathan PD; Mount Vernon Cancer Centre, Northwood, United Kingdom., Ribas A; Department of Medicine, University of California-Los Angeles, Los Angeles, California., Flaherty KT; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Karaszewska B; Przychodnia Lekarska Komed, Konin, Poland., Schachter J; The Ella Lemelbaum Institute for Immuno-Oncology and Melanoma, Sheba Medical Center, Tel Hashomer, and Sackler Medical School, Tel Aviv University, Tel Aviv, Israel., Sucker A; Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Schmid KW; Department of Pathology, University Hospital Essen, Essen, Germany.; Ruhrlandklinik, West German Lung Center, University Hospital Essen, University of Duisburg-Essen, Germany.; German Cancer Consortium, Heidelberg, Germany., Zimmer L; Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Livingstone E; Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Gasal E; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey., Schadendorf D; Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.; German Cancer Consortium, Heidelberg, Germany., Roesch A; Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. alexander.roesch@uk-essen.de.; German Cancer Consortium, Heidelberg, Germany.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Aug 15; Vol. 27 (16), pp. 4500-4510. Date of Electronic Publication: 2021 Jun 09.
Autor:
Syeda MM; NYU Langone Health, New York, NY, USA., Wiggins JM; NYU Langone Health, New York, NY, USA., Corless BC; NYU Langone Health, New York, NY, USA., Long GV; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia., Flaherty KT; Dana-Farber Cancer Institute/Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA., Schadendorf D; University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany., Nathan PD; East and North NHS Trust, Northwood, UK., Robert C; Institute Gustave Roussy and Paris-Sud University, Villejuif, France., Ribas A; Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, Los Angeles, CA, USA., Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Grob JJ; Dermatology and Skin Cancer Department, Aix-Marseille University, Marseille, France., Gasal E; Novartis Pharmaceuticals, East Hanover, NJ, USA., Squires M; Novartis Institute for BioMedical Research, Cambridge, MA, USA., Marker M; Novartis Pharmaceuticals, East Hanover, NJ, USA., Garrett J; Novartis Pharmaceuticals, Cambridge, MA, USA., Brase JC; Novartis Pharma, Basel, Switzerland., Polsky D; NYU Langone Health, New York, NY, USA. Electronic address: david.polsky@nyulangone.org.
Publikováno v:
The Lancet. Oncology [Lancet Oncol] 2021 Mar; Vol. 22 (3), pp. 370-380. Date of Electronic Publication: 2021 Feb 12.
Autor:
Müller, Anita1,2 (AUTHOR) anita.muller@curie.fr, Dolbeault, Sylvie2,3 (AUTHOR), Piperno-Neumann, Sophie4 (AUTHOR), Clerc, Morgane2 (AUTHOR), Jarry, Paulin5 (AUTHOR), Cassoux, Nathalie5,6,7 (AUTHOR), Lumbroso-Le Rouic, Livia5 (AUTHOR), Matet, Alexandre5,7,8 (AUTHOR), Rodrigues, Manuel4,9 (AUTHOR), Holzner, Bernhard10,11 (AUTHOR), Malaise, Denis5,8,12 (AUTHOR), Brédart, Anne1,2 (AUTHOR)
Publikováno v:
BMC Psychiatry. 11/15/2024, Vol. 24 Issue 1, p1-13. 13p.
Autor:
Ferrier, Sarah Tadhg1,2 (AUTHOR), Li, Mingyang1 (AUTHOR), Burnier, Julia V.1,2,3 (AUTHOR) Julia.burnier@mcgill.ca
Publikováno v:
BMC Cancer. 10/23/2024, Vol. 24 Issue 1, p1-18. 18p.